Similar articles

• Fertility control with norethindrone enanthate, a long-acting parenteral progestogen.

  Kesserü-Koós E, Larrañaga-Legufa A, Hurtado-Koo H, Scharff HJ. Kesserü-Koós E, et al. Acta Eur Fertil. 1973 Dec;4(4):203-21. Acta Eur Fertil. 1973. PMID: 4802108 No abstract available.
• Current perspectives on combination oral contraceptives.

  Smith MA, Youngkin EQ. Smith MA, et al. Clin Pharm. 1984 Sep-Oct;3(5):485-96. Clin Pharm. 1984. PMID: 6386284 Review.
• [Continuous low dose treatment with gestagen].

  Vihriälä A, Vuopala S. Vihriälä A, et al. Lakartidningen. 1974 May 22;71(21):2137-8. Lakartidningen. 1974. PMID: 4832361 Swedish. No abstract available.
• [Ovulation inhibition with low dosage gestagen components. Results of international clinical trial of Orlest].

  Figoureux J, Onghena G, Schlikker E, Wattiez M, Schlösser W, Vercautere E, William P. Figoureux J, et al. Munch Med Wochenschr. 1967 Dec 1;109(48):2555-8. Munch Med Wochenschr. 1967. PMID: 5631905 Clinical Trial. German. No abstract available.
• Depo Provera. Position paper on clinical use, effectiveness and side effects.

  Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M. Bigrigg A, et al. Br J Fam Plann. 1999 Jul;25(2):69-76. Br J Fam Plann. 1999. PMID: 10454658 Review.